STAAR Surgical (STAA) to Release Quarterly Earnings on Wednesday

STAAR Surgical (NASDAQ:STAA) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.25 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.12). The firm had revenue of $77.40 million for the quarter, compared to analyst estimates of $75.34 million. STAAR Surgical had a net margin of 4.69% and a return on equity of 6.83%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 earnings per share. On average, analysts expect STAAR Surgical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

STAAR Surgical Trading Down 2.1 %

NASDAQ STAA traded down $0.76 during trading on Tuesday, reaching $36.24. The company’s stock had a trading volume of 595,553 shares, compared to its average volume of 676,544. The stock has a market capitalization of $1.78 billion, a PE ratio of 119.35 and a beta of 0.59. STAAR Surgical has a 1-year low of $26.66 and a 1-year high of $52.68. The business has a 50-day moving average price of $42.14 and a 200-day moving average price of $39.72.

Wall Street Analysts Forecast Growth

STAA has been the subject of several recent analyst reports. BTIG Research upped their price target on STAAR Surgical from $46.00 to $53.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Monday, July 15th. Piper Sandler increased their target price on STAAR Surgical from $33.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, May 8th. Morgan Stanley cut STAAR Surgical from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $50.00 to $37.00 in a research report on Monday, July 15th. Finally, Mizuho increased their price target on shares of STAAR Surgical from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $48.00.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.